Cora Capital Advisors’s AstraZeneca AZN Stock Holding History

Cora Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$398K	Buy	+2,125	New	+$400K	0.11%	85
2026 Q1	–	Sell	-2,185	Closed	-$402K	–	137
2025 Q4	$402K	Buy	2,185 +197	+10%	+$34.6K	0.16%	72
2025 Q3	$305K	Buy	1,988 +6	+0.3%	+$908	0.13%	85
2025 Q2	$277K	Sell	1,982 -122	-6%	-$17.1K	0.12%	85
2025 Q1	$309K	Buy	2,104 +6	+0.3%	+$868	0.15%	75
2024 Q4	$275K	Buy	2,098 +6	+0.3%	+$840	0.13%	81
2024 Q3	$326K	Hold	2,092	–	–	0.16%	71
2024 Q2	$326K	Sell	2,092 -1	-0%	-$150	0.17%	67
2024 Q1	$284K	Hold	2,093	–	–	0.15%	73
2023 Q4	$282K	Sell	2,093 -28	-1%	-$3.64K	0.17%	75
2023 Q3	$287K	Sell	2,121 -3	-0.1%	-$410	0.19%	71
2023 Q2	$304K	Sell	2,124 -40	-2%	-$5.88K	0.2%	69
2023 Q1	$300K	Buy	2,164 +11	+0.5%	+$1.48K	0.22%	62
2022 Q4	$292K	Buy	+2,153	New	+$270K	0.2%	58

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cora Capital Advisors's AZN Position: Q2 2026 in Review

Cora Capital Advisors opened a new position in AstraZeneca (AZN) in Q2 2026: 2,125 shares worth $398K. The stake represents 0.11% of the portfolio and ranks #85 among its holdings. This is a return to the name: Cora Capital Advisors previously reported a position in AZN as recently as Q4 2025.

Cora Capital Advisors first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. The position peaked at $402K in Q4 2025. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cora Capital Advisors held 2,125 shares of AstraZeneca worth $398K as of Q2 2026.
AstraZeneca was a new Cora Capital Advisors position in Q2 2026.
AstraZeneca made up 0.11% of Cora Capital Advisors's portfolio in Q2 2026, its #85 holding.
Cora Capital Advisors first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
Cora Capital Advisors's AstraZeneca position peaked at $402K in Q4 2025.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cora Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.